[EN] OXYMETHYLENE ARYL COMPOUNDS FOR TREATING INFLAMMATORY GASTROINTESTINAL DISEASES OR GASTROINTESTINAL CONDITIONS<br/>[FR] COMPOSÉS D'ARYLE D'OXYMÉTHYLÈNE POUR LE TRAITEMENT DE MALADIES GASTRO-INTESTINALES INFLAMMATOIRES OU DE TROUBLES GASTRO-INTESTINAUX
申请人:CYMABAY THERAPEUTICS
公开号:WO2018026890A1
公开(公告)日:2018-02-08
Use of oxymethylene aryl GPRl 19 agonists, and optionally DPP IV inhibitors and optionally metformin, for the treatment of inflammatory gastrointestinal diseases or gastrointestinal conditions involving malabsorption of nutrients and/or fluids are provided.
[EN] PREPARATION OF 5-ETHYL-2-{4-[4-(4-TETRAZOL-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE<br/>[FR] PRÉPARATION DE 5-ÉTHYL-2-{4-[4-(4-TÉTRAZOL-1-YL-PHÉNOXYMÉTHYL)-THIAZOL-2-YL]-PIPÉRIDIN-1-YL}-PYRIMIDINE
申请人:METABOLEX INC
公开号:WO2011153435A1
公开(公告)日:2011-12-08
Processes and intermediates for the synthesis of 5-ethyl-2-4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine are provided.
[EN] OXYMETHYLENE ARYL COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS D'OXYMÉTHYLÈNE ARYLIQUE ET UTILISATIONS DE CEUX-CI
申请人:METABOLEX INC
公开号:WO2009123992A1
公开(公告)日:2009-10-08
Use of oxymethylene aryl GPR119 agonists and DPP IV inhibitors for the treatment of diabetic diseases, including Type II diabetes and other diseases associated with poor glycemic control are provided.
[EN] COMPOSITIONS OF 5-ETHYL-2-{4-[4-(4-TETRAZOL-1-YL-PHENOXYMETHYL)-THIAZOL-2-YL]-PIPERIDIN-1-YL}-PYRIMIDINE<br/>[FR] COMPOSITIONS DE 5-ÉTHYL-2-{4-[4-(4-TÉTRAZOL-1-YL-PHÉNOXYMÉTHYL)-THIAZOL-2-YL]-PIPÉRIDIN-1-YL}-PYRIMIDINE
申请人:METABOLEX INC
公开号:WO2011163090A1
公开(公告)日:2011-12-29
Non - crystalline 5 - ethyl -2- 4- [4- (4- tetrazol - 1 -yl -phenoxymethyl) - thiazol - 2 -yl] - piperidin - 1 -yl} -py rimidine, compositions thereof, methods for their preparation and use are disclosed.
HETEROCYCLIC RECEPTOR AGONISTS FOR THE TREATMENT OF DIABETES AND METABOLIC DISORDERS
申请人:Chen Xin
公开号:US20090054475A1
公开(公告)日:2009-02-26
Compounds and methods are provided for the treatment of, inter alia, Type II diabetes and other diseases associated with poor glycemic control. The compounds of the invention are orally active.